Navigation Links
Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
Date:1/16/2009

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters.

During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006.

"Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, PhD, senior vice president and general manager for the Healthcare business of Thomson Reuters.

The study is based on medical and drug claims data from the Thomson Reuters MarketScan(R) Research Databases. Results were weighted to reflect the U.S. population with employer-sponsored health insurance.

Researchers found a 50-percent increase in the use of prescription sleep aids among all adults under age 45 from 1998 to 2006. The most dramatic increase was seen in the youngest segment of the study population, those between the ages of 18 and 24, whose prevalence of use increased from 599 users per 100,000 in 1998 to 1,524 users per 100,000 in 2006. For those 25 to 34 years of age, use almost doubled from 1,372 users to 2,528 users per 100,000.

Non-benzodiazepine hypnotics -- such as Ambien CR and Lunesta -- accounted for almost two-thirds of all the prescription sleep aids used by this population.

A number of psychiatric, cognitive and conditioning factors are known to perpetuate insomnia, and the study found that 25 percent of first-time sleep aid users had a mental heath diagnosis in the month prior to sleep aid use. However, fewer than 10 percent of these new users visited a mental health professional prior to initiating sleep aid use. M
'/>"/>

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Healthcare Cancer Profiler Used in Study
2. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
6. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
7. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
8. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
9. VA-NIH Study Offers Hope for Parkinsons Patients
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Reproductive Partners Participates in New IVF Progesterone Delivery System Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., Dec. 3 A genetic varia...ing a potentially life-threatening blood disorder ...chemicals is one of several medical discoveries sc...stics (NYSE: DGX ) will present during the 51st ...g and Exposition, December 5-8, 2009, in New Orlea...
(Date:12/3/2009)...c. 3 BioMed Realty Trust...entered into a new lease with Regeneron Pharmaceut...,000 square feet of additional, newly-constructed ...tview campus in Tarrytown, New York. The new lease...l space was completed approximately two months aft...
(Date:12/3/2009)...OERSHOLM, Denmark and SAN DIEGO, California, Decem...fully Inhibits miR-122, a microRNA Important for,H...y Reducing Hepatitis C,Virus in the Bloodstream in...is C Virus , - SPC3649 Demonstrates Effic...rious Adverse Events in the Treated Animals - Sign...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 57780 1Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 57780 2Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 57780 3Thomson Reuters Launches Thomson Pharma Partnering Forecast 57778 1Thomson Reuters Launches Thomson Pharma Partnering Forecast 57778 2Nuvilex Inc Announced that Reme Flu 28TM 29 will Incorporate Proprietary Syn X9 28TM 29 Delivery Technology into its Product Formulation 14179 1Nuvilex Inc Announced that Reme Flu 28TM 29 will Incorporate Proprietary Syn X9 28TM 29 Delivery Technology into its Product Formulation 14179 2Nuvilex Inc Announced that Reme Flu 28TM 29 will Incorporate Proprietary Syn X9 28TM 29 Delivery Technology into its Product Formulation 14179 3
...armaceuticals, Inc.,(OTC Bulletin Board: ACCP) ann... using the company,s proprietary Cobalamin(TM) tec... an animal model of diabetes, through,its oral ins... Cobalamin,which is based upon the body,s natural ...tract, were tested in an animal model of diabetes....
...m 11 PROCRIT(R) (Epoetin alfa),studies will be pre... 49th,Annual Meeting and Exposition December 8 - 1...ghts including:, -- the potential impact on the n...ythropoiesis-stimulating agents (ESAs) for the tre...-- the use of PROCRIT in extended dosing regimens;...
Other Medicine Technology:Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 2Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 2PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 4PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 5PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 6PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 7PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 8PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 9
(Date:12/4/2009)... North American Seminars Inc....host continuing medical education courses at their...acility to showcase its operation and capabilities...overall costs to educate their physical therapy an...45 facilities hosted over 250 live training events...
(Date:12/4/2009)... The renowned Center for mind...ow offering the only natural immuno-boosting herba...les of Ayurveda. , San Di...s age of unprecedented illness due to factors such...nza strain millions of people around the world are...
(Date:12/3/2009)... With a membership increase o...his achievement not only as a milestone in its his...;s relevance. Most associations are experiencing a...my.,“At a time when trade organizations acr...he FMA is experiencing unprecedented growth, signa...
(Date:12/3/2009)... , MINNEAPOLIS, Dec. 3 Child...named a recipient of the 2009 Leapfrog Top Hospita... for delivering care that is among the best in the... efficiency. ,, The Leapfrog survey is the only...ssues including mortality rates for common procedu...
(Date:12/3/2009)... , BEVERLY HILLS, Calif., Dec. 3 /PRNewswire...s year,s Divine Design Gala and Premier Shopping E...be priced at 50-70% off regular prices. The event...h Monday, December 7, 2009, located at 9900 Wilshi...ls, California. Please visit www.divinedesign.or...
Breaking Medicine News(10 mins):Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:The Chopra Center for Wellbeing Launches Vedamune: An Ayurvedic Supplement to Support The Immune System 2Health News:Florida Medical Association Marks Record Membership Growth 2Health News:Children's Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 2Health News:Christian Audigier Represented at Divine Design for Project Angel Food 2
... begun to solve some of the mysteries of the commo...ic codes for all the known strains of the human rh...d School of Medicine in Baltimore and colleagues a... viruses are related, with their commonalities and...
... on moveable platform kept better balance in a sli...hDay News) -- Repeatedly exposing people to situat...em to maintain their balance on slippery floors an...gies that can be used in a variety of situations. ...
...Feb. 20 During the annual Promesa y Esperan...dio, the leading Spanish-language radio group, His...elp save kids battling cancer at St. Jude Childre...an $6 million in cash and pledges to help St. Jude...
..., Feb. 20 China Healthcare Acquisition Corp. (the... announced today that its Board of Directors has s...g the stockholders entitled to receive liquidatin...roceeds of the IPO were deposited. The Company ha...
...ecutive Acknowledges ,Tireless Determination, to F..., Businesses and Community Leaders to Collaborate ...Y, Calif., Feb. 20 Following six long weeks of ne...olicymakers, business, health care and other secto...
...ELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, 2...9, janderson@aan.com ,Jay Mac Bride, (651) 695-27...isk for Multiple Sclerosis , SEATTLE People who ... at the American Academy of Neurology,s 61st Annua...
Other Medicine News:Health News:Researchers crack the code of the common cold 2Health News:Researchers crack the code of the common cold 3Health News:Researchers crack the code of the common cold 4Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Hispanics Across the Country Pledge More Than $6 Million During Univision Radio Event to Help St. Jude Fight Childhood Cancer 2Health News:Hispanics Across the Country Pledge More Than $6 Million During Univision Radio Event to Help St. Jude Fight Childhood Cancer 3Health News:China Healthcare Acquisition Announces Record Date for Trust Fund Distribution 2Health News:Barry Arbuckle, PhD, MemorialCare Medical Centers CEO and Immediate Past Chair, California Hospital Association, Speaks Out on California Budget Passage 2
Lighted Pediatric Stylet - Non-Sterile
Lighted Orotracheal Stylet - Sterile
MICROSTIM PLUS Nerve Stimulator
Surch-Lite™ Flexible Light - 10" Non-Sterile
Medicine Products: